There is little information concerning the excretion of RVF virus from the natural orifices of infected animals, and the possibility of infection of suscep tible animals occurring through nasal, ocular, buccal, vaginal and rectal rou tes. Murphy et al. (13) infected lambs through the conjunctival sac and buccal mucosa. Walker et al. (14) found that the virus was shed in the saliva of infec-
Summary : The shedding of RVF virus was traced in 3 groups of sheep, one vaccinated twice with RVF vaccine, a second vaccinated twice with BCG tuberculosis vaccine, and a third unvaccinated group. The three groups were challenged with virulent R VF virus and the rectal tempera ture, viraemia and virus shedding were recorded in all animals of the three groups. A rise in rectal temperature was noticed in both the control and BCG double vaccinated groups, while it did not occur in the RVF double vac cinated group. Virus content of the serum of the R VF vaccinated group was too small to be estimated, but it reached 3 or more log w TCID 50 per ml in the con trol group and the BCG vaccinated group.
Virus shedding occurred in all groups after challenge, and the pro portion of swabs from which virus was recovered amounted to 30%, 22% and 31 % for the BCG vaccinated, R VF vaccinated and infected control groups, respectively. Virus titre in nasal, ocular and rectal swab samples was higher in the BCG vaccinated group than in the R VF vaccinated group.
There was little difference between groups in antibody titres measu red by complement fixation and neutralization tests 7 and 10 days after challenge.
There is little information concerning the excretion of RVF virus from the natural orifices of infected animals, and the possibility of infection of suscep tible animals occurring through nasal, ocular, buccal, vaginal and rectal rou tes. Murphy et al. (13) infected lambs through the conjunctival sac and buccal mucosa. Walker et al. (14) found that the virus was shed in the saliva of infec-ted puppies, but not in the urine. On the other hand, Mcintosh et al. (11) men tioned that the virus was shed by lambs and calves infected with the RVF virus, even in the absence of clinical signs. Imam et al. (10) claimed to have infected goats by inhalation, with recovery of the virus from rectal swabs.
Recently Abdel-Karim (1) demonstrated contact infection between infec ted and uninfected sheep.
Barakat et al. (2) proposed the use of BCG tuberculosis vaccine as an immunopotentiating agent against RVF virus infection among sheep in Egypt. They compared the reaction of three groups of sheep, one vaccinated with BCG vac cine, the second with inactivated RVF vaccine, and a third unvaccinated group, to a challenge dose of RVF virus, with reference to the rate and titre of virus isolation from nasal, ocular and rectals swabs collected after challenge inocu lation.
MATERIALS AND METHODS

BCG vaccine (used for human vaccination against tuberculosis).
This vaccine was produced by Japan BCG Laboratory, Tokyo, Japan, and obtained through the Egyptian Organization for Biological and Vaccine Pro duction, BCG Lab., Agouza, Cairo. The dose for sheep was the same as that recommended by the manufacturer for human beings.
RVF vaccine.
Each experimental animal was subcutaneously inoculated with 1 ml of a locally prepared, inactivated vaccine, previously tested in mice for safety and potency according to the technique described by El-Nimr et al. (7) and El-Nimr (8).
Virus.
RVF virus locally isolated from a human patient from Egypt (Zagazig strain) was propagated in BHK cells for the purpose of vaccine production. This cellculture virus has a titre of 10 78 TCID 50 per ml, when titrated in BHK cells. The challenging dose contained 10 s TCID 50 per ml.
Sheep.
Ten Ossimi sheep aged 9-18 months (males and females) were used. They were shown to be susceptible to RVF infection (by the serum neutralization test) and were tuberculin negative.
Virus, isolation.
For this purpose, swabs (nasal, ocular, rectal and vaginal) were collected during the 10 days observation period in sterile containers containing Hank's solution and antibiotics. The swab emulsions were centrifuged and the super natant fluid from each sample was inoculated into two test tubes of BHK mono layer cultures, which were examined daily for cytopathic changes.
Serological tests.
Serum samples were collected from each animal during the observation period, and the serum neutralization test (SNT) was performed in cell culture following the technique described by Walker (14) . In addition, the complement fixation test (CFT) was carried out by the technique described in "Laboratory book for complement fixation" (1962).
Experiment 1: BCG double vaccination.
This experiment included 4 animals previously inoculated twice with BCG vaccine 21 days apart (Group I). One month after the second inoculation, each animal was inoculated subcutaneously with 1 ml of RVF virus previously titra ted in tissue culture, and containing 10 5 TCID 50 per ml. The animals were bled daily for the next 10 days following the virus inoculation and each serum was separately collected and kept at -70°C till used. Rectal temperature was recor ded daily for each animal. Nasal, ocular, rectal and vaginal swabs were collec ted daily from each animal for virus isolation. At the end of the observation period, the animals were killed for pathological examination.
Experiment 2: RVF double vaccination.
This experiment included 3 animals (Group II) previously inoculated twice with locally prepared, inactivated RVF vaccine, 21 days apart. One month after the second inoculation, each animal was challenged with the same dose of RVF virus as that used in experiment I. The same observations as for experiment 1 were conducted. At the end of the observation period, the animals were slaugh tered for pathological examination.
Three unvaccinated animals of the same age (Group III) were kept as con trols, infected with the same dose of RVF virus and kept under observation for the same period as in experiments 1 and 2.
RESULTS
Virus isolation.
Results of RVF virus recovery from swabs collected from animals after chal lenge inoculation are presented in Table I and Figures 1 and 2 , from which it is clear that virus shedding occurred in all three groups of animals during the ten observation days. The cumulative rates of isolation were 30%, 22% and 31% for the experimental groups I, II and III. Virus was first isolated on the 2nd day in the BCG and infected control groups, but not until the 3rd day in the RVF vaccinated group. Maximum virus isolation was reached on the 4th day for BCG, 7th-9th days for RVF vaccinated group and the 5th day for the controls. Excretion of virus by control infected animals was mostly in nasal swabs. Vaginal shedding of virus occurred in female animals in groups II and III.
Infectivity titre of sera and excreta.
Results of this experiment are presented in Table II . It is clear from the table that infectivity titres of excreted virus are mostly less than log 1.0 TCID 50 in swabs from both vaccinated challenged groups. One BCG-vaccinated sheep showed a titre of log 3.5 in nasal excretion and log 2 in ocular swabs. In addi tion, one sheep, vaccinated with RVF vaccine gave a titre of log 2.0 TCID 50 in nasal swabs after challenge. At the same time, the control infected group showed approximate infective titres ranging from log 1.7 to 3.25 TCID S0 per ml.
Serological conversion.
Results of CF and SN tests are illustrated in Table III . The log NI 50 esti mated at 7 and 10 days after challenge showed little differences among groups. A slightly higher SN index was observed for the BCG-vaccinated group at 10 days and the same applied to the results of CFT. 
Group of animals
DISCUSSION
Rift Valley fever virus was isolated from nasal, ocular and rectal swabs in the three groups of animals (BCG double vaccinated, RVF double vaccinated and control groups). The cumulative rates of isolation were 30, 22 and 31%, respectively (Table I and Figures 1 and 2 ). The start of excretion and maxi mum virus isolation was somewhat later in the RVF vaccinated group than in the other two groups (BCG and control), but the virus still reached the excre tion sites via the circulation, even though it could not be detected in serum. This is supported by the very low virus titre in the three excreta (less than log 1.0 TCID 50 per ml). In the other two groups, whenever virus was detected in a serum sample, there was an appreciable titre in the relevant excreta. In the BCG vaccinated group, the highest titre (log 3.5 TCID 50 /ml) occurred in the corresponding nasal swabs.
RVF virus was isolated from the excreta of the three groups of animals, although their sera contained log 10 NI 50 of more than 2.0, a figure accepted by Easterday et al. (6) as a criterion of definite protection. If these animals are considered to be protected, what is the possibility of contact infection ? If susceptible animals came into close proximity with these virus excretor ani mals, there would be a possibility of subsequent infection. Although the accu mulated evidence appears to support the concept that all animals (except human beings) become infected with RVF through mosquito vectors, it has been shown that the disease may be experimentally produced by subcutaneous, intratesticular, intracutaneous, intramuscular and intravenous inoculation, as well as by nasal instillation, aerosol inhalation and the application of the virus to sca rified skin and conjunctiva (13, 6, 10) .
Observations concerning infection by contact and ingestion are inconsis tent. In this respect, Daubney et al. (3) failed to demonstrate contact transmis sion between lambs, and were unable to infect lambs by oral administration of infected blood. Moreover, Easterday et al. (6) were unable to establish infec tion by contact. On the other hand, Weiss (15) reported contact infection, and Walker et al. (14) mentioned successful direct transmission in dogs. Recently, Abdel-Karim (1) demonstrated contact infection in pregnant sheep, the incontact animals having a virus shedding rate of 18%, accompanied by viraemia and a titre of less than log 10 1.3.
Easterday (5) explained the apparent absence of contact infections by the failure to demonstrate virus in urine, faeces and milk from several species; simi lar observations had been reported by Daubney et al. (3) , Findlay (9) and later by Mims (12) .
The purpose of the present work is to evaluate the hazards to animal and public health by the excretion of virus from inoculated sheep, and to see whether vaccination of sheep with RVF or BCG vaccines would prevent or lessen the rate of virus shedding. The first question has been answered by recovering virus from swabs collected during the period after challenge.
As for the second question, this might depend upon factors such as the immune status of the animal, and the rate of viraemia in the vaccinated ani mals. In the present work, double vaccination with either BCG or RVF vacci nes provided good protection against the high dose of the virulent virus used for the challenge infection. Previous research has shown that BCG vaccine was effective in controlling the severity of infection and minimizing the losses as seen in "Seds" Farm (Beni Suif Governorate), i.e. subclinical infection, follow ed by specific immunity (2) . In addition, serological investigation of "Seds" Farm animals revealed that the RVF epidemic passed subclinically, because complement-fixing antibodies were present in random samples collected from this farm (titres betwen 1/8 and 1/16).
These facts emphasize the importance of the degree of immune status of the animal, if it is to withstand contact infection with a dose of virus equal to or very near that of the challenge dose used in the present work. Yet, one must keep in mind that RVF virus could be excreted from vaccinated animals even without any specific clinical symptoms. Adequate protection should be provided by vaccinating all the susceptible animals with a safe and potent RVF vaccine.
Combined vaccination with BCG and the inactivated RVF vaccine may have an immunopotentiating effect in susceptible animals. 
EXCRÉTION DU VIRUS DE LA FIÈVRE DE LA VALLÉE DU RIFT PAR DES OVINS INFECTÉS ET DES OVINS IMMUNISÉS PAR LE BCG ET LE VACCIN
